Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lofexidine PK in Buprenorphine Dose Reduction
NCT02801357Phase 1Completed
- Sponsor
- US WorldMeds
- Start
- Jun 2016
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lofexidine in opioid withdrawal syndrome (OWS), sponsored by US WorldMeds. Primary endpoint: Metabolite to Parent Plasma Concentration Ratios at Day 7. Started Jun 2016; status: completed.
02
Drugs
lofexidine
03
Conditions
opioid withdrawal syndrome (OWS)
Beyond the preview
Go deeper on NCT02801357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02801357.